Absorption, metabolism and excretion of 14C-emvododstat following repeat daily oral dose administration in human volunteers using a combination of microtracer radioactivity and high radioactivity doses.

Emvododstat is a potent inhibitor of dihydroorotate dehydrogenase and is now in clinical development for the treatment of COVID-19 and acute myeloid leukemia. Since the metabolism and pharmacokinetics of emvododstat in humans is time­dependent, a repeat dose study design using a combination of microtracer radioactivity and high radioactivity doses was employed to evaluate the metabolism and excretion of emvododstat near steady state. Seven healthy male subjects each received 16 mg/0.3 µCi 14C-emvododstat daily oral doses for 6 days followed by a 16 mg/100 µCi high radioactivity oral dose on Day 7. Following the last 16 mg/0.3 µCi 14C­emvododstat dose on Day 6, total radioactivity in plasma peaked at 6 h post-dose. Following a high radioactivity oral dose (16 mg/100 µCi) of 14C-emvododstat on Day 7, both whole blood and plasma radioactivity peaked at 6 h, rapidly declined from 6 h to 36 h post-dose, and decreased slowly thereafter with measurable radioactivity at 240 h post-dose. The mean cumulative recovery of the administered dose was 6.0% in urine and 19.9% in feces by 240 h post-dose, and the mean extrapolated recovery to infinity was 37.3% in urine and 56.6% in feces. Similar metabolite profiles were observed after repeat daily microtracer radioactivity oral dosing on Day 6 and after a high radioactivity oral dose on Day 7. Emvododstat was the most abundant circulating component, M443 and O-desmethyl emvododstat glucuronide were the major circulating metabolites; M474 was the most abundant metabolite in urine, while O­desmethyl emvododstat was the most abundant metabolite in feces. Significance Statement This study provides a complete set of the absorption, metabolism and excretion data of emvododstat, a potent inhibitor of dihydroorotate dehydrogenase, at close to steady state in healthy human subjects. Resolution of challenges due to slow metabolism and elimination of a lipophilic compound highlighted in this study can be achieved by repeat daily microtracer radioactivity oral dosing followed by a high radioactivity oral dosing at therapeutically relevant doses.

Synthesis, Structure, Magnetic Behavior, and Mössbauer Spectroscopy of Two New Iron(II) Spin-Transition Compounds with the Ligand 4-Isopropyl-1,2,4-triazole. X-ray Structure of [Fe(3)(4-isopropyl-1,2,4-triazole)(6)(H(2)O)(6)](tosylate)(6).2H(2)O.

Two new iron(II) compounds with the formula [Fe(3)(iptrz)(6)(H(2)O)(6)]X(6).xH(2)O (with iptrz = 4-isopropyl-1,2,4-triazole and X = p-toluenesulfonate (Tos) or trifluoromethanesulfonate (Trifl)) were synthesized. The crystal structure of [Fe(3)(iptrz)(6)(H(2)O)(6)](Tos)(6).2H(2)O (I) has been solved at room temperature. Crystals of I are triclinic, space group P&onemacr; with a = 12.8820(11) Å, b = 15.580(2) Å, c = 24.445(4) Å, alpha = 79.270(12) degrees, beta = 86.688(11) degrees, gamma = 83.007(8) degrees, Z = 2. The structure of I consists of linear trinuclear cations with a +6 charge and noncoordinated anions and lattice water molecules. The central iron ion is located on an inversion center and is coordinated by 6 nitrogen atoms of 6 iptrz molecules bridging via the nitrogen atoms in the 1,2-positions. Each external iron atom completes its coordination sphere with three coordinated water molecules. The temperature dependent magnetic measurements of compound I and [Fe(3)(iptrz)(6)(H(2)O)(6)](Trifl)(6) (II) show that both compounds exhibit a gradual spin conversion of the central iron ion centered at T(1/2) = 242 K for I and 187 K for II. Temperature dependent Mössbauer spectroscopy measurements on I show the behavior expected for a compound of this nature. The measurements on II indicate a strong influence of the spin conversion of the central iron ion on both external iron ions. The nature of this phenomenon is proposed to be connected to a very rigid lattice structure (ionic, H-bonding) connecting the trinuclear units.